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ABSTRACT (249/250) 
Background: In self-controlled case series (SCCS) the event should not condition the probability of 
subsequent exposure. If this assumption is not met, an important bias could take place. The association 
of hip/femur fracture (HFF) and use of benzodiazepines (BDZ) has a bidirectional causal relationship and 
can serve as case study to investigate the impact of this methodological issue. 
Objectives: To assess the magnitude of bias introduced in a SCCS when HFF conditions the posterior 
exposure to BDZ and explore ways to correct it. 
Methods: 4,450 cases of HFF who had at least one BZD prescription were selected from the primary care 
health record database BIFAP. Exposure to BZD was divided into non-use, current, recent and past use. 
Conditional Poisson regression was used to estimate incidence rate ratios (IRR) of HFF among current vs. 
non-use/past, adjusted for age. To investigate possible event-exposure dependence, a pre-exposure time 
of different lengths (15, 30 and 60 days) was excluded from the reference category to evaluate the IRR. 
Results: IRR of HHF for current use was 0.79 (0.72-0.86); removing 30 days IRR was 1.43 (1.31-1.57). 
Removing 15 days, IRR was 1.29 (1.18-1.41) and removing 60 days, IRR was 1.56 (1.42-1.72). A pre-
exposure period up to 182 days was necessary to remove such effect giving an IRR of 1.64 (1.48-1.81).  
Conclusions: HFF remarkably conditioned the use of BDZs resulting in seriously biased IRRs when this 
association was studied through a SCCS design. The use of pre-exposure periods of different lengths 




1. INTRODUCTION  
The self-controlled case series (SCCS) method was developed initially to investigate the effect of 
vaccination and acute potential adverse events1, but it has been applied later on in other areas of 
pharmacoepidemiology2, to investigate transient exposures with acute and non-acute outcomes, 
employing only individuals who experienced the outcome of interest. 
The SCCS design follows the cohort design approach, where events occur randomly during the observation 
period, and the follow up of each patient is divided according to exposure status. A key difference from a 
traditional cohort is that all patients in an SCCS have both the exposure and the outcome of interest. The 
rate of outcomes during exposed time is compared against the rate in unexposed time to determine if 
there is an association with the exposure. The method is derived from a Poisson model by conditioning 
on the individual total number of events and exposure history. It is self-matched and hence all time 
invariant confounders are implicitly controlled for3. As a consequence of this conditioning, the effects of 
fixed covariates cancel out, so that the method has a particular advantage compared with cohort and 
case-control studies4 and it is being used increasingly in pharmacoepidemiology 5-11. Potential 
confounders that change over time and are measurable can also be controlled for. 
Among the assumptions required by this method, one is that the occurrence of an event must not alter 
the probability of subsequent exposure. To ensure this assumption, a “pre-exposure” time risk window 
can be created to examine whether the exposure depends or not on the occurrence of the outcome. As 
the selection of that risk window may impact the estimates, it is important to assess different period 
lengths to observe the effect12.  
This assumption and the one that the event does not influence the length of observation period, have 
been explored recently by Whitaker et al.13 to investigate the robustness of results obtained using SCCS 
when these two assumptions are not met. 
In a previous study within the IMI-PROTECT project comparing case-only designs10, we observed this pre-
exposure time bias and the aim of the present study is to measure and characterise the impact of this bias 
and show how to correct it. We explored the risk in the reference category to avoid the under/over 
estimation of the relative risk if the assumption above is not met. As a case study we used the well-
established association of benzodiazepines and related drugs (BZD) with hip/femur fractures (HFF), as it 
is normally a transient exposure and with this design some confounding such as frailty could be addressed.  
2. METHODS 
2.1 Data source 
The study was performed in the Spanish BIFAP database. It is an electronic healthcare records database 
from primary care, operated by the Spanish Medicine Agency (AEMPS), with fully anonymised clinical 
information. BIFAP contains demographic and administrative data; medical information including 
diagnosis, test results and referrals; prescriptions; deaths; and other data on smoking, weight, height and 
alcohol abuse. For this study, data up to 2009 was used, with information from about   4 million patients. 
Systematic quality controls are in place to reach an up-to-standard level valid for research and several 
validation studies14-17 have been performed with this database (http://www.bifap.org/summary.php).  
2.2 Study population 
The study period was considered from the 1st January 2001 until 31st December 2009. We included all 
patients who had a recorded diagnosis of HFF (“cases”) and had at least one prescription of BZD during 
the study period. In many studies the index date coincides with the start date, but in this study design, 
the event will occur randomly during the study period, and not at the start date, that is why we named 
them differently. The start date was the date patients met the following criteria: 1) At least one year of 
enrolment with the general practitioner (GP); 2) age ≥18 years old; and 3) 12 months free of hip/femur 
fracture (HFF) and 6 months free of exposure to BZD before the start date. And the index date was the 
date on which the HFF occurred. The outcome was searched in the BIFAP database using the International 
Classification of Primary Care: ICPC-2, code L75 and then validated through manual review.   
2.3 Exposure definition 
To ascertain the exposure of interest the Anatomical Therapeutic Chemical (ATC) classification system was 
used (http://www.whocc.no/atc_ddd_index/). All drugs pertaining to ATC codes N05BA (Anxiolytics -
Benzodiazepine derivatives), N05CD (Hypnotics and sedatives - Benzodiazepine derivatives), N05CF 
(Hypnotics and sedatives - Benzodiazepine related drugs) and N05CM02 (Other hypnotics and sedatives - 
Clomethiazole) were included as exposure of interest.  
Duration of each prescription was estimated based on the prescribed amount and daily dose. The 
expected duration of use was calculated following the methods described by Gardarsdottir et al 18. When 
a gap of more than 30 days occurred between the theoretical end date of a prescription and the date of 
the subsequent prescription, exposure was deemed to be discontinuous and a new treatment episode 
was considered. 
The person-time of each patient was divided according to their exposure into periods of current, recent, 
past and non-use. Thus, current use was the period from the start of a BZD prescription until 30 days after 
the estimated end date of the supply and it was further divided into five risk time windows: 1-30, 31-60, 
61-182, 183-365 and >365 days; recent use was the period up to 60 days after current use; past use was 
the period after recent use until the patient became again a current user or the end of follow-up; non-use 
was the period between the start date and the first BZD prescription within the study period 
(supplementary Figure 1s). Combined non-use and past use were considered the reference category. 
Among current users, the exposure was stratified by the type of BZD: anxiolytics, hypnotics or both. 
2.4 Potential confounders 
Age was considered as the only potential confounder, assuming it accounts for most unmeasured time 
varying effects, if any.  
2.5 Analysis 
A conditional Poisson regression analysis was used to estimate the relative risk in terms of incidence 
rate ratios (IRRs) with corresponding 95%CI 19. Small age bands were created to allow adequate 
adjustment. A first age band was created for 18-29 years of age, and then 5-year age bands for patients 
up to 59 years of age, and finally one-year age bands for patients from 60 to 95 years, after which the 
final age band summarised age for the oldest age group (>95 years). The observation period of each 
participant was divided into risk windows according to their exposure to BZD and was further divided to 
control for age. 
Initially, IRRs were calculated by comparing the rate of HFF experienced during exposure periods with the 
rate of events during periods of past/non-use. For this analysis, only the first event (HFF) that occurred 
within the study period was considered, to meet the SCCS method assumption that events are 
independent. 
Then, to investigate the possible event-exposure dependence, a "pre-exposure" period of 30 days (normal 
length of a BZD prescription) was created before each beginning treatment episode, to remove this time 
from the reference category and correct for the potential effect that this dependence might cause 
(Supplementary - Figure 1s). The IRRs were estimated in the same way as before, excluding this pre-
exposure time from the reference category. 
Besides, to examine whether the length of that "pre-exposure" time risk window affected the risk of 
developing an HFF, the analysis was repeated with two different lengths. One shorter than previously with 
a length of 15 days, and one longer with a length of 60 days. 
Additionally, we estimated the extension of the risk in the reference category (past/non-use), dividing the 
time before the exposure in periods of 7 days until the pre-exposure IRR was ≤ 1. We then removed this 




The final study population was made up of 4,450 patients who had a recorded diagnosis of HFF and at 
least one prescription of BZD within the observation period. Patients had a median duration of the 
observation period of 1,956 days (5.4 years). 
Age ranged from 18-106 years old, with a mean (± SD) age of 74.5 (13.6) years old and a mean (± SD) age 
at first exposure of 76.4 (13.6) years old. About 77% were women. From all cases, 35% had an HFF during 
the exposure to BZD, with a median duration of exposure to BZD of 360 days. Distribution by sex and age 
in 10-years band categories, co-morbidities and co-medications at baseline are shown in Table 1. 
Osteoporosis; previous fractures; malignant neoplasms; ischemic heart disease; cerebrovascular disease; 
chronic obstructive pulmonary disease and anaemia, were the most frequent co-morbidities for this study 
population. 
Regarding co-medication collected at baseline, the most used drugs were antihypertensives (21.6%); 
diuretics (12.8%); and proton pump inhibitors (11.8%), followed by glucose-lowering drugs; 
antidepressants; non-steroidal anti-inflammatory drugs; statins; and bronchodilators, in a proportion 
between 5-10%. 
3.1. Risk of HFF associated with BZD use 
Crude and adjusted by age IRRs of HFF comparing exposed/unexposed periods were estimated in the 
absence of a pre-exposure window. A reduced risk of HFF was observed in the adjusted analysis over all 
time windows of current use [0.79 (0.72, 0.86)]. Similarly, a reduced risk was observed for use of 
anxiolytics or hypnotics when stratified by type of BZD [1.02 (0.81, 1.30)] (Table 2).When we examined 
whether the exposure was dependent on the event, excluding a time window of 30 days from the 
reference category, a remarkable pre-exposure risk was found (IRR adjusted by age= 6.47 (95%CI: 5.91-
7.09), giving an increased risk of HFF associated with BZD of 1.43 (1.31, 1.57). In addition, changes in the 
length of the pre-exposure time risk window had a relevant impact on the risk of having an HFF associated 
to current use of BZD, reaching an adjusted IRR of 1.56 (1.42, 1.72) when the pre-exposure time 
considered was 60 days (Table 3).  
3.2. Estimating the extension of the pre-exposure time. 
We divided the pre-exposure time in periods of 7 days until no increased risk was found. Then, we 
removed this time from the reference category and repeated the analysis. The time before the exposure 
was studied up to 210 days. A decreasing curve was observed, with lower ‘pre-exposure’ risks as long as 
the pre-exposure 7-day interval moved away of the starting of current use (Figure 1).  
Beyond the 26th interval (IRR= 0.9; 95%CI: 0.46-1.72) no increased ‘pre-exposure’ risk was observed. 
Hence the whole period between that interval and the exposure (182 days) was removed from the 
reference category.  
3.3. Risk of HFF associated with BZD after adjusting for the pre-exposure time  
In the adjusted analysis, the risk associated with current use was 1.64 (95%CI: 1.48-1.81). The current use 
of both, anxiolytics and hypnotics exhibited a higher risk of HFF (2.22; 95%CI: 1.75-2.82), as compared to 
the current use of either single subgroup (Table 4).  
 
 
3.4. Assessment of BZD use before and after the HFF 
Among 1,185 patients who had an HFF and use of BZD within 2 months around the HFF date, we 
observed that 36% patients started before and 64% started after the HFF, showing a peak around 10-20 
days after the event (Figure 2). 
4. DISCUSSION 
In the present study we found that many patients who sustained an HFF were newly prescribed a BZD 
after such event. This dependence between the exposure and the outcome represents a violation of one 
of the key assumptions of the SCCS design. Consequently, we observed that the risk of the reference 
period was contaminated with a high pre-exposure risk, increasing the risk of the reference category and 
diluting the risks of all other exposure categories. When such pre-exposure time was removed from the 
reference period, we corrected for this bias and the risk associated with current use reversed from a 
protective association to the expected harmful increased risk.  
The association of BZD use and HFF is an important public health problem which has been addressed 
multiple times with different designs. Most studies obtained an increased risk, but the magnitude of the 
effect varies considerably. In the PROTECT project20 one of the objectives was to investigate this event-
pair association (BZD-HFF) employing different designs and databases. As a result, we carried out a cohort 
study, and a nested case-control (NCC) study, in 3 different databases (BIFAP- Spain; CPRD-UK and 
Mondriaan-Netherlands) and compared our estimates with other published cohort and case-control 
studies. The pooled risk of 22 studies, including published cohort and case-control studies21 22 and the 
results from our three cohort studies, was 1.33 (1.23–1.43) with I2 = 84.2%23. This association was also 
explored in the Observational Medical Outcomes Partnership (OMOP) project 24. Interestingly, in seven 
out of ten DBs the researchers found no risk of hip fracture associated with BZD use when a SCCS was 
employed, similar to our initial results. Such a lack of effect may be related to the strong dependence of 
event and exposure, as we have shown.  
This phenomenon has also been described in other settings. Gibson et al 19, in a study of motor vehicle 
crashes and use of medications, found the highest risk in the pre-exposure time category, including the 
date of the first prescription, and then progressively decreased in recent and past use. This marked 
association of all medications in the 28 days up to and including the date of the first prescription, is 
consistent with the issue of prescriptions as a consequence of involvement in a motor vehicle crash.  
After exploring the length of the pre-exposure time window, we observed that the closer time window (7 
or 15 days), the higher risks found (7 days >15 days >30 days >60 days), reflecting the high number of new 
users of BZD found after a hip/femur fracture. A similar situation with SCCS design and hip/femur fracture 
as an outcome was observed by Lai C et al 25 where they examined prescriptions of alpha blockers 
following hip/femur fractures. 
Further exploring the risk before the exposure, it was found that apart from the intense risk just before 
the exposure, there was some ‘pre-exposure’ risk up to 182 days prior to the exposure. Once this period 
was removed, the results in the SCCS were similar to the ones found in a case crossover (CXO) design, 
performed as part of the same project (PROTECT) where we compared different designs across different 
databases thus, for the SCCS we observed an IRR=1.64 (95%CI: 1.48-1.81) and for the CXO, an OR=1.47 
(95%CI: 1.29-1.67).  
We have demonstrated the importance of exploring the assumptions in this study design and would 
recommend evaluating this potential bias whenever a SCCS is conducted. For this we would suggest 
estimating first the IRR of the event of interest associated with a particular exposure, and then repeat 
this calculation removing an estimate time window from the reference time (e.g. the standard length of 
the exposure prescription, in our case it was 30 days). If the IRRs before and after removing that time 
window are very different, this may indicate that the exposure is conditioned by the event and results 
may be biased.  Histograms, plotting the number of outcomes centred around the day of exposure can 
also be informative (ref https://www.crcpress.com/Self-Controlled-Case-Series-Studies-A-Modelling-
Guide-with-R/Farrington-Whitaker-Weldeselassie/p/book/9781498781596). 
 
The main limitations of the study are as follows: 1) The exposure to BZD was based on prescription dates, 
rather than the precise use dates, which is common in databases used in pharmacoepidemiology; It is 
therefore possible that exposure periods are misclassified to some extent, with both exposed and 
unexposed periods affected to some degree. The effect of this misclassification, if non-differential with 
respect to the outcome, would bias results towards the null, and so it is possible that we have 
underestimated any real effect of treatment with BZD, 2) Results from this study might not be 
extrapolated to other settings and certainly not be generalised to other drug-event pairs. 
5. CONCLUSIONS 
Case-only designs may offer better control for time invariant confounding factors than traditional designs 
and are a useful choice when intrinsic factors may represent relevant confounding, and when the effects 
of transient exposures are to be measured. However, care is needed to ensure the underlying assumptions 
of these designs are met. A specific assumption of SCCS design is that the event should not alter the 
probability of being exposure. When this is not met, the reference period could be spuriously associated 
with an increased/decreased ‘pre-exposure’ risk and, as a result, the risks of all other exposure categories 
would be under/overestimated. A thorough exploration of the appropriate pre-exposure period length is 
required to account for this.  
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Table 1- Baseline characteristics of the study population. 
 
Total SCCS population N=4,450 % 
Age (years) 
18 - 29 57 1.28 
30 - 39 100 2.25 
40 - 49 134 3.01 
50 - 59 254 5.71 
60 - 69 540 12.13 
70 - 79 1,531 34.4 
80 - 89 1,563 35.12 
90+ 271 6.09 
Sex 
Male 1,038 23.33 
Female 3,412 76.67 
Co-morbidities 
Osteoporosis 385 8.65 
Paget's disease 12 0.27 
Previous fractures 383 8.61 
Fractures during BZD exposure 1,543 34.67 
Rheumatoid arthritis 47 1.06 
Anaemia 230 5.17 
Epilepsies/ seizures 49 1.10 
Syncope 133 2.99 
IHD 341 7.66 
CVA 317 7.12 
Malignant neoplasms 372 8.36 
IBD 13 0.29 
COPD 248 5.57 
Liver disease 60 1.35 
Chronic renal failure 81 1.82 
Mental disorders (no depression) 49 1.10 
Dementia and/ or Alzheimer's disease 174 3.91 
Co-medications    
Glucocorticoids 33 0.74 
Bisphosphonates 92 2.07 
Raloxifene 10 0.22 
Strontium ranelate 0 0.00 
Parathyroid hormone 1 0.02 
Vitamin D + Ca supplements 179 4.02 
Calcitonin 37 0.83 
Antidepressants 316 7.10 
Antipsychotics/ Lithium 132 2.97 
Anti-Parkinson drugs 87 1.96 
Anticonvulsants 105 2.36 
Inhaled glucocorticoids 85 1.91 
Bronchodilators  235 5.28 
Anti-arrhythmics 52 1.17 
Sedating antihistamines 24 0.54 
Antihypertensive drugs 962 21.62 
Diuretics 570 12.81 
HRT 14 0.31 
Thyroid hormones 62 1.39 
Antithyroid drugs 9 0.20 
DMARDs 27 0.61 
Thiazolidinediones 2 0.04 
Other glucose-lowering drugs 340 7.64 
Antiemetics 41 0.92 
Anticoagulants 156 3.51 
Morphine/ opiates 156 3.51 
NSAIDs  311 6.99 
Statins 271 6.09 
PPIs 526 11.82 
Aromatase Inhibitors 11 0.25 
 
Abbreviations: BZD: Benzodiazepines and related drugs; IHD: Ischemic Heart disease; CVA: 
Cerebrovascular accident; IBD: Inflammatory bowel disease; COPD: Chronic Obstructive Pulmonary 
Disease; HRT: Hormone-replacement therapy; DMARDs: Disease-modifying antirheumatic drugs; NSAIDs: 













Table 2- Risk of hip-femur fracture associated with benzodiazepine use overall in different current use 
windows and according to the ATC subgroup when no pre-exposure period was considered.  
  
SCCS Model Crude  Model Adjusted by age 
Exposure Cases          Py IRR  95%         CI IRR  95%          CI 
Past/Non use (ref) 2,615 5,169,764 1.00     1.00     
Recent use 292 476,812 1.14 1.00 1.29 0.97 0.85 1.10 
Current 1-30d 213 409,985 0.92 0.80 1.07 0.79 0.68 0.92 
Current 31-60d 201 362,943 0.99 0.85 1.15 0.85 0.73 0.99 
Current 61-182d 314 614,880 0.93 0.82 1.06 0.75 0.66 0.86 
Current 183-365d 246 437,601 1.11 0.95 1.29 0.83 0.71 0.96 
Current >365d 569 1,120,123 1.28 1.12 1.47 0.73 0.63 0.84 
Current use 1,543 2,945,532 1.02 0.94 1.11 0.79 0.72 0.86 
Type of BZD by ATC subgroup      
Current use of 
anxiolytics 
1,023 1,985,997 1.01 0.91 1.11 0.80 0.72 0.88 
Current use of 
hypnotics 
333 645,533 0.96 0.82 1.13 0.72 0.61 0.84 
Current use of 
both  









Table 3- Comparison of incidence rate ratios (IRRs) of hip/femur fracture associated with 
benzodiazepine current use adjusted by age with different lengths of the pre-exposure time:  15, 30, and 
60 days. 
 
 SCCS   
Pre-exposure time  
15 days 
Pre-exposure time  
30 days 
Pre-exposure time  
60 days 
     
Exposure IRR15* 95% CI IRR30 95% CI IRR60 95% CI 
Past/non use 1.00     1.00     1.00     
Recent use 1.13 0.97 1.32 1.21 1.03 1.42 1.25 1.05 1.49 
Pre-Exposure 8.32 7.54 9.17 6.47 5.91 7.09 5.06 4.64 5.52 
Current use 1.29 1.18 1.41 1.43 1.31 1.57 1.56 1.42 1.72 
 
  
Table 4- Risk of hip-femur fracture associated with the use of benzodiazepine and related drugs, when 
a pre-exposure period of 182 days was excluded. 
 
SCCS Analysis without  
pre-exposure risk 
Crude Model Model Adjusted by age 
Exposure Cases Py IRR (95%) CI IRR (95%) CI 
Past/Non use  1,315 4,109,390  1.00 (ref.)       1.00 (ref.)   
182-day pre-
exposure 
1,300 1,060,374 3.95 3.63 4.29 3.68 3.38 4.01 
Current 1-30d 213 409,985 1.86 1.60 2.17 1.60 1.37 1.87 
Current 31-
60d 
201 362,943 2.00 1.71 2.34 1.71 1.46 2.00 
Current 61-
182d 
314 614,880 1.92 1.67 2.21 1.56 1.36 1.80 
Current 183-
365d 
246 437,601 2.31 1.98 2.70 1.75 1.49 2.06 
Current 
>365d 
569 1,120,123 2.71 2.35 3.13 1.62 1.38 1.89 
Current use 1,543 2,945,532 2.10 1.91 2.31 1.64 1.48 1.81 
Type of BZD by ATC subgroup 
Current use of 
anxiolytics 
1,023 1,985,997 2.06 1.85 2.30 1.65 1.47 1.85 
Current use of 
hypnotics 
333 645,533 1.95 1.66 2.29 1.48 1.25 1.75 
Currrent use 
of both  







Figure 1- Risk before the exposure to benzodiazepine. The scale starts at exposure time (0) and then 30 

















Figure 2 - People started a BZD treatment before and after the hip/femur fracture. The red line indicates 
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